KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Alteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: The HOPE Randomized Clinical Trial.

Ying Zhou, Yaode He, Bruce C V Campbell, David S Liebeskind, Changzheng Yuan, Hui Chen, Yanxing Zhang, Tingyu Yi, Zhongyu Luo, Zuowen Zhang, Changcai Meng, Jianhua Cheng, Hezhong Ouyang, Jin Hu, Fei Wang, Sheng Zhang, Qi Fang, Haitao Hu, Xuting Zhang, Yi Chen, Wansi Zhong, Maarten G Lansberg, Shenqiang Yan, Min Lou, HOPE investigators

JAMA 334(9) 788-797

PMID40773205
PMCIDPMC12332759
DOI10.1001/jama.2025.12063
发表日期2025-08-07
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:森林图/亚组分析图。
摘要

摘要

IMPORTANCE: The safety and efficacy of intravenous thrombolytics beyond 4.5 hours after ischemic stroke onset remain inadequately studied. OBJECTIVE: To evaluate the safety and efficacy of intravenous alteplase administered 4.5 to 24 hours after stroke onset in patients with salvageable brain tissue, regardless of the presence of large vessel occlusion. DESIGN, SETTING, AND PARTICIPANTS: This randomized, open-label, blinded end-point trial was conducted at 26 stroke centers across China. A total of 372 patients with acute ischemic stroke and salvageable brain tissue identified by perfusion imaging were enrolled between June 21, 2021, and June 30, 2024 (final follow-up October 2, 2024). Eligibility criteria included stroke onset (or the midpoint between last known well and symptom recognition if onset was unknown) of 4.5 to 24 hours prior to presentation, and no initial plan for endovascular thrombectomy. Data were analyzed from December 2024 to February 2025. INTERVENTIONS: Patients were randomly assigned (1:1) using a minimization algorithm to receive intravenous alteplase (0.9 mg/kg; maximum dose, 90 mg; n = 186) or standard medical treatment (n = 186). MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was functional independence, defined as a modified Rankin Scale score of 0 to 1 at 90 days. Safety outcomes included symptomatic intracranial hemorrhage within 36 hours and all-cause mortality within 90 days. RESULTS: Among 372 patients who were enrolled (median [IQR] age, 72 [64-80] years; 160 [43%] women), all completed the trial. The primary outcome occurred in 75 of 186 patients (40%) in the alteplase group and 49 of 186 (26%) in the control group (adjusted risk ratio, 1.52 [95% CI, 1.14-2.02]; P = .004; unadjusted risk difference, 13.98% [95% CI, 4.50%-23.45%]). The incidence of symptomatic intracranial hemorrhage was higher with alteplase at 3.8% compared with 0.51% with standard treatment (adjusted risk ratio, 7.34 [95% CI, 1.54-34.84]; P = .01; unadjusted risk difference, 3.23% [0.28%-6.19%]), and mortality was 11% in both groups (adjusted risk ratio, 0.91 [95% CI, 0.52-1.62]; P = .76; unadjusted risk difference, 0% [95% CI, -6.30% to 6.30%]). CONCLUSIONS AND RELEVANCE: In patients with acute ischemic stroke with salvageable brain tissue identified by perfusion imaging who did not initially receive thrombectomy, intravenous alteplase administered 4.5 to 24 hours after onset provided functional benefit, despite an increase in symptomatic intracranial hemorrhage. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04879615.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Flow of Patient Recruitment, Randomization, and Follow-Up in the HOPE Trial CT indicates computed tomography. To convert glucose to mg/dL, multiply mmol/L values by 0.0555. a Randomization was conducted using a centralized, web-based system employing a stochastic minimization algorithm, with stratification based on age (<70 or ≥70 years), time from symptom onset to randomization (<9 or ≥9 hours), and National Institutes of Health Stroke Scale (NIHSS) score at randomization (<10 or ≥10). b One patient crossed over to the standard treatment group and received rescue thrombectomy. c Seven patients were excluded due to protocol violations, including 4 who crossed over to the standard treatment group, 1 with infarct size >1/3 middle cerebral artery (MCA) territory, and 2 who received rescue thrombectomy. d Fifteen patients were excluded due to protocol violations, including 4 who crossed over to the alteplase group, 3 with infarct size >1/3 MCA territory, 1 with a history of ischemic stroke in the previous 3 months, and 7 who received rescue thrombectomy.
非 KM Figure
Figure 2Figure 2.. Distribution of Modified Rankin Scale Scores at 90 Days Scores on the modified Rankin Scale (mRS) range from 0 to 6, with higher scores indicating greater disability. A score of 0 indicates no symptoms; 1, symptomatic but nondisabled; 2, disabled but independent; 3, dependent but ambulatory; 4, not ambulatory nor capable of body self-care; 5, severe disability requiring constant care; and 6, death. Percentages may not total to 100 because of rounding.
非 KM Figure
Figure 3Figure 3.. Subgroup Analyses for the Primary Outcome in the Primary Analysis Population Scores on the modified Rankin Scale (mRS) range from 0 to 6, with higher scores indicating greater disability. The National Institutes of Health Stroke Scale (NIHSS) scores range from 0 to 42, with higher scores indicating greater severity of neurological deficits. Stroke classification was determined based on medical history, clinical presentation, and available imaging findings. Large artery atherosclerosis was further categorized by anatomical location as intracranial or extracranial.
非 KM Figure